Zolendronic Acid

ApprovedSmall molecule

Zolendronic Acid is one of 91 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoblastic LeukemiaActive, not recruiting

Breast CancerActive, not recruiting

OsteoporosisActive, not recruiting

Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Breast CancerApproved

Active, not recruiting

OsteoporosisApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zolendronic Acid

Novartis

Approved

2 2

Tecentriq

Roche

Preclinical

36 3

MS Contin

Merck & Co.

Preclinical

2 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Zinecard

CChildren's Oncology Group

Preclinical

2 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Tricor

JJagotec

Preclinical

1 9

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 10

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Osteoporosis

NCT06643780

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

Unknown status·WWales Cancer Trials Unit·Phase 3·NCT00326820·1,404 enrolled

Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer

Terminated· Novartis logo

Novartis·Phase 4·NCT00375752·168 enrolled

Acute Lymphoblastic Leukemia1 trial

Zometa Study in Pediatric Acute Lymphoblastic Leukemia

Completed·—·Phase 3·NCT01656512·95 enrolled

Osteoporosis1 trial

RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis

Recruiting·PPrince of Wales Hospital, Shatin, Hong Kong·Phase 4·NCT06643780·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Zolendronic Acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zolendronic Acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zolendronic Acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Zolendronic Acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Breast Cancer2 trials

Acute Lymphoblastic Leukemia1 trial

Osteoporosis1 trial

References

Drug Info

Quick Facts

Related News